Long-Acting GLP-1 RAs Exenatide (Bydureon) In 1987, scientists discovered that GLP-1 promotes insulin secretion, and five years later, an entero-insulin analogue, Exendin-4, which is 53% homologous to GLP-1, was isolated from the saliva of the Mexican giant lizard, later known as exenatide, which has GLP-1 receptor agonist activity and a half-life of 2.4 hours
Contra-Actions Common effects post treatment: Inflammation of the treatment area is to be expected
TB500 for 4 to 8 weeks
This suggests a potential connection between GLP-1 therapy and reduced circulating tumor activity, raising questions about whether these medications may play a supportive role in oncology care beyond weight management
Well wishes, The B12Team
In June 2024, Teva Pharmaceuticals announced the launch of the first generic version of a GLP-1 receptor agonist in the United States, specifically liraglutide 1.8 mg